The antiestrogen tamoxifen (tam) is the most frequently used drug in breast cancer management today. Unfortunately its use is limited by the eventual development of acquired resistance in all patients, by mechanisms that are largely unknown. Clinical evidence as well as preliminary data from our laboratory, using both human breast cancer cells in an in vivo nude-mouse model as well as clinical samples from patients, suggests that """"""""tam resistance"""""""" is associated with the acquired ability of tam over time to stimulate rather than to inhibit tumor growth. This tam-stimulated growth is characterized by lower tam levels in tumor extracts and by an altered tam metabolite profile in the tumor. These data have led us to the hypothesis that one mechanism of acquired tam resistance is altered uptake and metabolism of tam by the tumor itself, leading to a relative abundance of estrogenic metabolites that then stimulate tumor growth. To further test our hypothesis, the following specific aims are proposed: 1. To identify and quantify tam and its antiestrogenic and estrogenic metabolites in tam sensitive and tam resistant tumors in the nude mouse model. These studies will determine whether acquired tam resistance is due to decreased accumulation of drug in the tumor, induction of tam metabolism, and/or accumulation of known estrogenic metabolites within the tumor itself. 2. To serially measure tam and its metabolites in tumor, liver, uterus, and serum to determine whether an altered metabolic profile with time signals the appearance of resistance. We will also determine whether tumor metabolism or systemic metabolism is primarily responsible for the altered tumor metabolite, profile characteristic of resistance. 3. To determine if acquired tam resistance can be reversed or whether antiestrogen resistance can be delayed by new steroidal antiestrogens, non-isomerizable tam analogs, or newly synthesized tam analogs designed to chemically block conversion to estrogenic metabolites. 4. To test the hypothesis that reduced tam accumulation in resistant tumors is due to an active efflux mechanism, and to determine if tam resistant tumors show cross resistance to other chemotherapeutic agents. 5. To quantify tam and its metabolites in serum, peripheral leukocytes, and tumors from patients who are responding to tam compared to those with acquired resistance, in order to confirm that a similar pattern of altered tam metabolism is also observed in patients. These studies will yield new and important information on the mechanisms of acquired tamoxifen resistance and its possible reversal that will have immediate clinical application for breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA030251-12
Application #
3169150
Study Section
Physiological Sciences Study Section (PSF)
Project Start
1981-07-01
Project End
1995-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
12
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Osborne, C K (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-18
Nicholson, R I; Gee, J M; Bryant, S et al. (1996) Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci 784:325-35
Osborne, C K; Coronado-Heinsohn, E B; Hilsenbeck, S G et al. (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-50
Maenpaa, J; Wiebe, V; Wurz, G et al. (1994) Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance. Cancer Chemother Pharmacol 35:149-52
Osborne, C K; Jarman, M; McCague, R et al. (1994) The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95
Koester, S K; Maenpaa, J U; Wiebe, V J et al. (1994) Flow cytometry: potential utility in monitoring drug effects in breast cancer. Breast Cancer Res Treat 32:57-65
Sipila, P E; Wiebe, V J; Hubbard, G B et al. (1993) Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo. Eur J Cancer 29A:2138-44
Maenpaa, J U; Wurz, G T; Baker, W J et al. (1993) A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin. Oncol Res 5:461-6
Encarnacion, C A; Ciocca, D R; McGuire, W L et al. (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-46
Osborne, C K (1993) Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47:83-9

Showing the most recent 10 out of 33 publications